In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic
about
In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporinSingle-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)Recent bioanalytical methods for quantification of third-generation cephalosporins using HPLC and LC-MS(/MS) and their applications in pharmacokinetic studies.In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.In vitro activities and targets of three cephem antibiotics against Haemophilus influenzaeAntimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients.LY164846 in vitro antimicrobial activity testing, including disk diffusion susceptibility tests using 30-microgram disksPharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiencyInterpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.Cefixime disk susceptibility test criteria.Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.Cefaclor: a contemporary look at susceptibility of key pathogens from around the globe.Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.World-wide development of antibiotic resistance in pneumococci.Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester.Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins.In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.BMY 28100, a new oral cephalosporin.Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.In vitro susceptibility of Haemophilus influenzae to cefixime.In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.Phase I study of cefixime, a new oral cephalosporin.Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.False resistance results using 5 micrograms cefixime disks to test Haemophilus influenzae.Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.In vitro antibacterial properties of cefetamet and in vivo activity of its orally absorbable ester derivative, cefetamet pivoxil.Automatic phylogenetic classification of bacterial beta-lactamase sequences including structural and antibiotic substrate preference information.Treatment of Sinus Empyema in Adults: A Coordinated Nordic Multicenter Trial of Cefixime vs. Cefaclor
P2860
Q24676500-5DC30562-267F-421C-851E-6865CAB45A8EQ34631585-69688B8B-D43D-4CC4-B554-B9F66A481F69Q35297977-A71D8BF0-A5A3-4C18-BDE9-326D77571214Q35311343-386D306B-F58F-4CB8-82EB-180C21AB18FDQ35326715-16FC9F99-A096-4298-8CE8-EC4C62173B84Q35343778-85774482-CEA1-4C8B-843B-F005946EE683Q35358847-BE44FA68-6C35-4FE0-BA9F-E19A7C81C6F1Q35564509-44E502FB-F1FD-40E6-8FA7-7EFD5EA5E136Q35565470-439567B7-E721-40A6-83D1-E798F481B689Q35649259-4C2E6A90-51A4-4024-AC05-6303E6741FD6Q35653211-FEEFCAE7-68BD-4D75-BCA9-D5011A8AA0ADQ37139121-E706605C-C686-42C4-8B46-A97719035F81Q37211155-B73276FF-CEC5-467F-899C-23AFD577CEF2Q37219636-99933B08-F489-4120-832F-66B1E0C926C1Q38551015-C7DF8B0A-2E37-4A1A-B27B-56677F02373DQ39472196-B19A5BD2-476B-45D1-B522-375ED6F81AE8Q39673641-5353020E-9FAE-4E68-8147-1A445C95563EQ39815649-2D8AD24B-AED5-41EB-ACB6-4FD5C8836E5DQ39817382-FD3579EA-7AF9-4151-9AB2-0F09FE328A29Q39818163-CC761421-0419-4148-BD65-7F8E0A07C79BQ39827644-2CCC149D-49D0-4615-8C48-E33F6319BE89Q39827862-63696105-089F-4209-B5B8-04B52E1BC72BQ39828400-63F3A6C8-49B8-41C6-BF5A-35DD8FA6F2A6Q39829121-85E537DC-7ED9-46AF-AEA8-A8FA6DA47CA3Q39832345-CDB2BFD1-AF67-4872-B41F-A50272211E90Q40286255-101C88CE-BBD3-4F86-8A88-9837B57EADBBQ44783271-6963BFC8-082B-42D2-96A1-4825C9CB03BAQ54276749-0898608C-47F8-47E5-B0F5-7CFCE64364B2Q54293002-CFBA2A6C-07A8-46BF-B862-5A83ED4AD747Q54313093-91622299-D33A-461F-8F58-21BACC10B133Q54353071-BEF001F9-937D-4877-8E2B-A3EB714E8371Q54393142-96CDAE51-F1BB-4024-91B6-8B1FBF924245Q58255276-2883D30D-4729-4F8B-9B40-2639FD2B1C45
P2860
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic
description
1984 nî lūn-bûn
@nan
1984 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@ast
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@en
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@nl
type
label
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@ast
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@en
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@nl
prefLabel
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@ast
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@en
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@nl
P2093
P2860
P356
P1476
In vitro and in vivo antibacte ...... rally active cephem antibiotic
@en
P2093
P2860
P304
P356
10.1128/AAC.25.1.98
P407
P577
1984-01-01T00:00:00Z